Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML)
Status:
Completed
Trial end date:
2015-03-31
Target enrollment:
Participant gender:
Summary
This study has been designed to investigate the safety and feasibility of using a
chemotherapy drug, Clofarabine, to reduce the disease burden before a donor transplant, in
patients with high risk Acute Myeloid Leukaemia or Myelodysplasia (MDS). In this study
Clofarabine chemotherapy will be given a few days before a reduced or full intensity donor
stem cell transplant and without waiting for normal blood counts to recover. It is hoped that
this approach may improve the outcome for patients with high risk AML and MDS after their
transplant.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University Hospital Southampton NHS Foundation Trust